Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1

被引：0
|
作者：
Marchand, M
van Baren, N
Weynants, P
Brichard, V
Dréno, B
Tessier, MH
Rankin, E
Parmiani, G
Arienti, F
Humblet, Y
Bourlond, A
Vanwijck, R
Liénard, D
Beauduin, M
Dietrich, PY
Russo, V
Kerger, J
Masucci, G
Jäger, E
De Greve, J
Atzpodien, J
Brasseur, F
Coulie, PG
Van der Bruggen, P
Boon, T
机构：
[1] Clin Univ St Luc, Ludwig Inst Canc Res, Brussels Branch, B-1200 Brussels, Belgium
[2] Catholic Univ Louvain, Cellular Genet Unit, Brussels, Belgium
[3] Catholic Univ Louvain, Clin Univ St Luc, Dept Oncol, Brussels, Belgium
[4] Catholic Univ Louvain, Clin Univ Mont Godinne, Dept Pneumol, B-3000 Louvain, Belgium
[5] CHU Nantes, Hotel Dieu, Dept Dermatol, Nantes, France
[6] Antoni Van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Oncol, Amsterdam, Netherlands
[7] Inst Nazl Studio & Cura Tumori, Div Expt Oncol D, Milan, Italy
[8] CHU Vaudois, Ludwig Inst Canc Res, Lausanne Branch, CH-1011 Lausanne, Switzerland
[9] CHU Vaudois, Ctr Pluridisciplinaire Oncol, Lausanne, Switzerland
[10] Hop Jolimont, Dept Oncol & Nucl Med, Haine St Paul, Belgium
[11] Hop Cantonal Univ Geneva, Dept Oncol, CH-1211 Geneva, Switzerland
[12] H San Raffaele, Gene Therapy Unit, Milan, Italy
[13] Free Univ Brussels, Inst Jules Bordet, Dept Oncol, Brussels, Belgium
[14] Karolinska Inst, Radium Hemmet, Dept Oncol, Stockholm, Sweden
[15] Krankenhaus NW Frankfurt, Med Klin 2, Dept Hematol & Oncol, Frankfurt, Germany
[16] Free Univ Brussels, Akad Ziekenhuis, Dept Oncol, Brussels, Belgium
[17] Hannover Med Sch, Dept Hematol & Oncol, Hannover, Germany
来源：
INTERNATIONAL JOURNAL OF CANCER | 1999年 / 80卷 / 02期
关键词：
D O I：
10.1002/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.0.CO;2-S
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Thirty-nine tumor-bearing patients with metastatic melanoma were treated with 3 subcutaneous injections of the MAGE-3.A1 peptide at monthly intervals. No significant toxicity was observed. Of the 25 patients who received the complete treatment, 7 displayed significant tumor regressions. All but one of these regressions involved cutaneous metastases. Three regressions were complete and 2 of these led to a disease-free state, which persisted for more than 2 years after the beginning of treatment. No evidence for a cytolytic T lymphocyte (CTL) response was found in the blood of the 4 patients who were analyzed, including 2 who displayed complete tumor regression. Our results suggest that injection of the MAGE-3.A1 peptide induced tumor regression in a significant number of the patients, even though no massive CTL response was produced. (C) 1999 Wiley-Liss, Inc.
引用
收藏
页码：219 / 230
页数：12
相关论文
共 26 条
  • [1] Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3
    Marchand, M
    Weynants, P
    Rankin, E
    Arienti, F
    Belli, F
    Parmiani, G
    Cascinelli, N
    Bourlond, A
    Vanwijck, R
    Humblet, Y
    Canon, JL
    Laurent, C
    Naeyaert, JM
    Plagne, R
    Deraemaeker, R
    Knuth, A
    Jager, E
    Brasseur, F
    Herman, J
    Coulie, PG
    Boon, T
    INTERNATIONAL JOURNAL OF CANCER, 1995, 63 (06) : 883 - 885
  • [2] A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3
    Coulie, PG
    Karanikas, V
    Colau, D
    Lurquin, C
    Landry, C
    Marchand, M
    Dorval, T
    Brichard, V
    Boon, T
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (18) : 10290 - 10295
  • [3] A PEPTIDE ENCODED BY HUMAN GENE MAGE-3 AND PRESENTED BY HLA-A2 INDUCES CYTOLYTIC T-LYMPHOCYTES THAT RECOGNIZE TUMOR-CELLS EXPRESSING MAGE-3
    VANDERBRUGGEN, P
    BASTIN, J
    GAJEWSKI, T
    COULIE, PG
    BOEL, P
    DESMET, C
    TRAVERSARI, C
    TOWNSEND, A
    BOON, T
    EUROPEAN JOURNAL OF IMMUNOLOGY, 1994, 24 (12) : 3038 - 3043
  • [4] A MAGE-3 peptide recognized on HLA-B35 and HLA-A1 by cytolytic T lymphocytes
    Schultz, ES
    Zhang, Y
    Knowles, R
    Tine, J
    Traversari, C
    Boon, T
    van der Bruggen, P
    TISSUE ANTIGENS, 2001, 57 (02): : 103 - 109
  • [5] Characterization of antigenic peptides presented by HLA-B44 molecules on tumor cells expressing the gene MAGE-3
    Fleischhauer, K
    Fruci, D
    VanEndert, P
    Herman, J
    Tanzarella, S
    Wallny, HJ
    Coulie, P
    Bordignon, C
    Traversari, C
    INTERNATIONAL JOURNAL OF CANCER, 1996, 68 (05) : 622 - 628
  • [6] Analysis of a rare melanoma patient with a spontaneous CTL response to a MAGE-A3 peptide presented by HLA-A1
    Takeshi Hanagiri
    Nicolas van Baren
    Bart Neyns
    Thierry Boon
    Pierre G. Coulie
    Cancer Immunology, Immunotherapy, 2006, 55 : 178 - 184
  • [7] Analysis of a rare melanoma patient with a spontaneous CTL response to a MAGE-A3 peptide presented by HLA-A1
    Hanagiri, T
    van Baren, N
    Neyns, B
    Boon, T
    Coulie, PG
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2006, 55 (02) : 178 - 184
  • [8] A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein
    Zhang, Y
    Chaux, P
    Stroobant, V
    Eggermont, AMM
    Corthals, J
    Maillère, B
    Thielemans, K
    Marchand, M
    Boon, T
    van der Bruggen, P
    JOURNAL OF IMMUNOLOGY, 2003, 171 (01): : 219 - 225
  • [9] A phase I trial of an HLA-A1 restricted MAGE-3 epitope peptide with incomplete Freund's adjuvant in patients with resected high-risk melanoma
    Weber, JS
    Hua, FL
    Spears, L
    Marty, V
    Kuniyoshi, C
    Celis, E
    JOURNAL OF IMMUNOTHERAPY, 1999, 22 (05) : 431 - 440
  • [10] New MAGE-4 antigenic peptide recognized by cytolytic T lymphocytes on HLA-A1 tumor cells
    Kobayashi, T
    Lonchay, C
    Colau, D
    Demotte, N
    Boon, T
    van der Bruggen, P
    TISSUE ANTIGENS, 2003, 62 (05): : 426 - 432
123